William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating on July 31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors that highlight Arcellx Inc’s promising developments and strong clinical data. The iMMagine-1 trial has shown impressive results with 18-month progression-free survival and overall survival rates that are competitive with existing therapies, indicating a strong efficacy and safety profile for Anito-cel.
Additionally, the clearance of Arcellx’s second ARC-SparX program, ACLX-004, by the FDA for IND is a significant milestone. This program offers a modular platform for CAR-T therapies that could address current challenges such as CAR-induced toxicities and tumor heterogeneity. These advancements, along with the anticipated updates from the iMMagine-1 study, support the positive outlook for Arcellx’s future growth and development.
In another report released on July 31, Scotiabank also maintained a Buy rating on the stock with a $133.00 price target.